Developments in the apheresis procedure for the treatment of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 12, Issue 5 SUPPL. 1, 2006, Pages

  Pineda, Alvaro A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adacolumn; Apheresis; Cellsorba; Granulocytes; Inflammatory bowel disease; Leukocytapheresis; Monocytes

Indexed keywords

CELLULOSE ACETATE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; APHERESIS; CELL MATURATION; CELL SURVIVAL; CENTRIFUGATION; COST OF ILLNESS; CROHN DISEASE; CYTOKINE PRODUCTION; DOWN REGULATION; ENTERITIS; GRANULOCYTE; HUMAN; LEUKAPHERESIS; LEUKOCYTE; MEMBRANE FILTER; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 30344436177     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000195386.19268.b3     Document Type: Review

References (28)

1. Eshleman JR, Silberstein LE. The development of selective plasmapheresis as a means for specific therapeutic intervention. Transfusion. 1991;31:96-98.
2. Lazarus HM, Cohen SB, Clegg DO, et al. Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients. Transfusion. 1991;31:122-128.
3. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995;30:322-329.
4. Bicks RO, Groshart KD. Editorial: the current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease. J Clin Gastroenterol. 1989;11:136-138.
5. Bicks RO, Groshart KD, Chandler RH. The treatment of severe chronically active Crohn's disease by T-8 (suppressor cell) lymphapheresis. Gastroenterology. 1985;88:A1325.
6. Bicks RO, Groshart KD, Luther RW. Total parenteral nutrition (TPN) plus T-lymphocyte apheresis (TLA) in the treatment of severe chronic active CD. Gastroenterology. 1988;94:A34.
7. Daibutsu M, Takagi T, Ogawa H, et al. Treatment of chronic rheumatoid arthritis by lymphocytapheresis. Ther Plasmapheresis. 1987;7:257-260.
8. Suemitsu J, Yashia M, Yamawaki N, et al. Leukocytapheresis therapy by extracorporeal circulation using a leukocyte removal filter. Ther Apher. 1998;2:31-36.
9. Hirayama A, Nagase S, Ueda A, et al. Oxidative stress during leukocyte absorption apheresis. J Clin Apheresis. 2003;18:61-66.
10. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis. 2001;16:1-9.
11. Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderate-to-severe ulcerative colitis. Digestion. 2004;70:36-44.
12. Saniabadi A, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48-59.
13. Matsui T, Nishimura T, Matake H, et al. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol. 2003;98:511-512.
14. Sawada K, Ohnishi K, Kosaka T, et al. Leukocytapheresis with leukocyte removal filter therapy for ulcerative colitis. Ther Apher. 1997;1:207-211.
15. Sands BE, Sandborn WJ, Wolf DC, et al. Pilot study on safety and effectiveness of granulocyte/monocyte adsorption apheresis with Adacolumn in patients with inflammatory bowel disease. Poster presented at: American College of Gastroenterology 6th Annual Scientific Meeting; October 29 to November 3, 2004; Orlando, Fla.
16. Shirokaze J. Leukocytapheresis using a leukocyte removal filter. Ther Apher. 2002;6:261-266.
17. Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology. 1978;74:501-503.
18. Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994;35:669-674.
19. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991;86:489-493.
20. Sawada K. Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Dis Colon Rectum. 2003;46:S66-S77.
21. Brannigan A, Connell PR, Hurley H, et al. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock. 2000;13:361-366.
22. Nikolaus S, Bauditz J, Gionchetti P, et al. Increased secretion of proinflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut. 1998;42:470-476.
23. Lampinen M, Carlson M, Sangfelt P, et al. IL-5 and TNF-α participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci. 2001;46:2004-2009.
24. Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002;47:1334-1341.
25. Cassatella M. The production of cytokines by polymorphonuclear neutrophils. Immunol Today. 1995;16:21-26.
26. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
27. Tibble JA, Sigthorsson G, Bridger D, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
28. Beers MH, Berkow R. Thrombocytopenia. In: The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck & Co; 2004. Available at: http://www.merck.com. Accessed January 21, 2005.